Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies to treat autoimmune diseases. Their leading product candidate, voclosporin, has the potential to address unmet medical needs in the treatment of lupus nephritis. With a strong pipeline and a commitment to innovation, Aurinia Pharmaceuticals is poised to make a significant impact in the field of autoimmune disease therapeutics.
